Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Investigating the role of ENPP1 in breast cancer progression

EF 2024-25

Résumé
Breast cancer is the most frequently diagnosed cancer in women and the leading cause of cancer death in women worldwide. While immunotherapies, agents that harness the immune system to fight cancers, have revolutionized treatment for other types of cancer, it remains largely unsuccessful in treating breast cancer. This is because immunotherapy requires the presence of immune cells in the tumour to be efficacious, and many subtypes of breast cancer do not meet this requirement. These subtypes are termed immune-cold due to their low levels of immune cell infiltration into the tumour, resulting in unresponsiveness to immunotherapies. One immune-cold subtype in particular, Luminal B, is commonly associated with poor prognosis. It has been observed that increasing the number of immune cells that enter the tumour is associated with better patient outcomes, therefore it is imperative to understand what mediates the exclusion of immune cells from breast tumours. The protein ENPP1 was found to be upregulated in primary breast tumours in comparison to normal tissue and was previously determined to be involved in immune suppression. However, the role of ENPP1 in breast cancer progression and response to therapy remains unknown, particularly in the Luminal B subtype. We aim to delete the ENPP1 gene in mice and study the effects on the tumour progression. We also plan on treating mice with an ENPP1 inhibitor to study the potential of ENPP1 as a therapeutic target both alone and in combination with other immunotherapies. Our findings will thus shed light on the potential for ENPP1 as a novel therapeutic target that can improve the utility of immunotherapies for breast cancer patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529805
Name
Echavez Clarisse Dane
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of ENPP1 in breast cancer progression
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Enpp1; Immunotherapy; Oncology
Abstract
Breast cancer is the most frequently diagnosed cancer in women and the leading cause of cancer death in women worldwide. While immunotherapies, agents that harness the immune system to fight cancers, have revolutionized treatment for other types of cancer, it remains largely unsuccessful in treating breast cancer. This is because immunotherapy requires the presence of immune cells in the tumour to be efficacious, and many subtypes of breast cancer do not meet this requirement. These subtypes are termed immune-cold due to their low levels of immune cell infiltration into the tumour, resulting in unresponsiveness to immunotherapies. One immune-cold subtype in particular, Luminal B, is commonly associated with poor prognosis. It has been observed that increasing the number of immune cells that enter the tumour is associated with better patient outcomes, therefore it is imperative to understand what mediates the exclusion of immune cells from breast tumours. The protein ENPP1 was found to be upregulated in primary breast tumours in comparison to normal tissue and was previously determined to be involved in immune suppression. However, the role of ENPP1 in breast cancer progression and response to therapy remains unknown, particularly in the Luminal B subtype. We aim to delete the ENPP1 gene in mice and study the effects on the tumour progression. We also plan on treating mice with an ENPP1 inhibitor to study the potential of ENPP1 as a therapeutic target both alone and in combination with other immunotherapies. Our findings will thus shed light on the potential for ENPP1 as a novel therapeutic target that can improve the utility of immunotherapies for breast cancer patients.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Echavez, Clarisse Dane
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~